• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Web App Boosts Survival for Lung Cancer Patients

Publication
Article
Evidence-Based OncologyJuly 2016
Volume 22
Issue SP10

Patients with lung cancer who participated in a Web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols, according to a study presented at the annual meeting of the American Society of Clinical Oncology.

Patients with lung cancer who participated in a Web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols, according to study results presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO).

The MoovCare system made a difference for patients because it resulted in early detection of dangerous conditions or recurrences, resulting in healthier individuals who were better able to undergo optimal therapy and earlier supportive care that improved their quality of life, said lead study author Fabrice Denis, MD, PhD, during an ASCO press cast. The median overall survival (OS) rate for patients who used the MoovCare system was 19 months compared with 12 months for participants in the control group (HR, 0.325; P = .0025), after 20 months of follow-up. Additionally, 75% of the patients followed through MoovCare were still alive at 1 year versus 49% with standard procedures.

There also was a 50% reduction in the average number of imaging tests per patient per year with the use of the app, said Denis, a researcher at the Institut Interrégional de Cancérologie Jean Bernard in Le Mans, France. These improvements were achieved even though the relapse rates were similar for both groups: 49% among those who used the app and 51% among those with typical follow-up, researchers reported. However, performance scores stayed higher among patients who used MoovCare. As a result, 74% of these patients were able to undergo optimal therapy upon relapse compared with 33% who had not used the app (P<.001).

The complete article can be accessed here: http://bit.ly/2ae60kD.

Anita T. Shaffer is the managing editor of OncologyLive.

Related Videos
Mike Brown, Vice President of Managed Care, Cardinal Health
Mike Brown, vice president of managed services at Cardinal Health
Mike Brown, vice president of managed services, Cardinal Health
Brian Mullen, PhD, head of innovation and product, The Clinic by Cleveland Clinic
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
Mike Brown, Vice President of Managed Care at Cardinal Health
Dr Kathi Mooney
Andrew Srisuwananukorn, MD
dr sara horst
Mike Koroscik, MBA, MHA, Allina Health and the Allina Health Cancer Institute
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.